en · de · es · fr · pt
sr9009-notes.peptides3626.com › Blog › Sr9009 Identity And Mechanism — Research Overview

Sr9009 Identity And Mechanism — Research Overview

By Editorial Desk · published 2026-01-30 · last reviewed 2026-03-02 · Blog

Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-03-02. Where a claim depends on a specific study, the study is described rather than over-claimed.

SR9009 Identity and Mechanism

SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.

SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.

REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.

SR9009 Handling and Quality Control

Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.

SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.

Sr9009 at a glance

PropertyValueNotes
Common nameSR9009Also marketed informally as Stenabolic
Chemical classSynthetic REV-ERB agonistBinds REV-ERBα and REV-ERBβ
Molecular formulaC24H30ClN3O4SApproximate molecular weight 492 g/mol
CAS Registry Number1379686-30-2Identifier for the parent compound
Regulatory statusNot approved for human useProhibited in sport by WADA

Analytical and Handling Considerations

Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.

SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.

Related pages on this site

Analytical Detection and Stability

Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.

Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.

Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.

Supporting material

===== Explantation deformity ===== The autologous fat graft replacement of breast implants (saline and silicone) resolves medical complications such as: capsular contracture, implant shell rupture, filler leakage (silent rupture), device deflation, and silicone-induced granulomas, which are medical conditions usually requiring re-operation and explantation (breast implant removal). The patient then has the option of surgical or non-implant breast corrections, either replacement of the explanted breast implants or fat-graft breast augmentation. Moreover, because fat-grafts are biologically sensitive, they cannot survive in the empty implantation pocket, instead, they are injected to and diffused within the breast-tissue matrix (recipient site), replacing approximately 50% of the volume of the removed implant – as permanent breast augmentation. The outcome of the explantation correction is a bust of natural appearance; breasts of volume, form, and feel, that – although approximately 50% smaller than the explanted breast size – are larger than the original breast size, pre-procedure.

Haemoglobin electrophoresis is a test that can detect different types of haemoglobin. Haemoglobin is extracted from the red cells, then introduced into a porous gel and subjected to an electrical field. This separates normal and abnormal haemoglobin, which can then be identified and quantified. Isoelectric focusing (IEF) is a technique that can be used to diagnose sickle cell disease and other hemoglobinopathies. The technique separates molecules based on their isoelectric point, or the pH at which they have no net electrical charge. IEF uses an electric charge to separate and identify different types of haemoglobin, which become focused into sharp, stationary bands. The technique can distinguish many types of abnormal haemoglobin. High-performance liquid chromatography (HPLC) is reliable, fully automated, and able to distinguish most types of sickle cell disease, including heterozygous. The method separates and quantifies haemoglobin fractions by measuring their flow rate through a column of absorbent material. DNA analysis using polymerase chain reaction (PCR), to amplify small samples of DNA. Variants of PCR used to diagnose sickle cell disease include amplification-refractory mutation system (ARMS) and allele-specific recombinase polymerase amplification. These tests can identify subtypes of sickle cell disease as well as combination hemoglobinopathies.

Loughren (1923), electrical engineer, former president of the Institute of Radio Engineers Leslie White (1923), anthropologist known for his theories of the evolution of culture and for the scientific study of culture John Gassner (1924), historian of theater, Sterling Professor at Yale University Meyer Schapiro (1924), art historian Joseph Campbell (1925), mythologist Jerome Klein (1925), art historian and co-founder of the American Artists' Congress William York Tindall (1925), James Joyce scholar at Columbia University Lionel Trilling (1925), literary critic Dwight C. Miner (1926), historian Jacques Barzun (1927), cultural historian Elliott Van Kirk Dobbie, historian, scholar of Anglo-Saxon literature Robert C.

=== Treating trauma and painful wounds === Persistent chronic pain associated with non-healing wounds is caused by tissue (nociceptive) or nerve (neuropathic) damage and is influenced by dressing changes and chronic inflammation. Chronic wounds take a long time to heal and patients can experience chronic wounds for many years. Chronic wound healing may be compromised by coexisting underlying conditions, such as venous valve backflow, peripheral vascular disease, uncontrolled edema and diabetes mellitus. If wound pain is not assessed and documented it may be ignored and/or not addressed properly. It is important to remember that increased wound pain may be an indicator of wound complications that need treatment, and therefore practitioners must constantly reassess the wound as well as the associated pain. Optimal management of wounds requires holistic assessment. Documentation of the patient's pain experience is critical and may range from the use of a patient diary, (which should be patient driven), to recording pain entirely by the healthcare professional or caregiver. Effective communication between the patient and the healthcare team is fundamental to this holistic approach. The more frequently healthcare professionals measure pain, the greater the likelihood of introducing or changing pain management practices. At present there are few local options for the treatment of persistent pain, whilst managing the exudate levels present in many chronic wounds.

Sources: en.wikipedia.org

Notes from published material

The laurel is an evergreen shrub or small tree, variable in size and sometimes reaching 7–18 m (23–59 ft) tall. The genus Laurus includes three accepted species, whose diagnostic key characters often overlap. The bay laurel is dioecious (unisexual), with male and female flowers on separate plants. Each flower is pale yellow-green, about 1 cm (3⁄8 in) diameter, and they are borne in pairs beside a leaf. The leaves are glabrous, 6–12 cm (2–5 in) long and 2–4 cm (3⁄4–1+5⁄8 in) broad, with an entire (untoothed) margin. On some leaves the margin undulates. The fruit is a small, shiny black drupe-like berry about 1 cm (3⁄8 in) long that contains one seed.

2024 South Africa: The National Consumer Commission recalled various peanut butter brands due to contamination 2012-2024 Kenya: A 13 year study conducted was the evaluation of total aflatoxins and aflatoxins B1 in peanut kernels, peanut butter, cashew nuts, and macadamia nuts. During 2021 to 2024, the Study showed that 59 to 74% of nut samples had exceeded the regulatory limits. However, some improvements were seen.

of the body weight W in kg, finding an average rho-factor of 0.68 for men and 0.55 for women. This ρm has units of dose per body weight (g/kg) divided by concentration (g/kg) and is therefore dimensionless. However, modern calculations use weight/volume concentrations (g/L) for EBAC, so Widmark's rho-factors must be adjusted for the density of blood, 1.055 g/mL. This

Sources: en.wikipedia.org

Further detail

Grinners Food Systems Limited, the franchiser of Greco Pizza (since 1981) and Captain Sub, is a Truro, Nova Scotia-based company. It is owned by Trucorp Investments Incorporated. Trucorp, headquartered in Dieppe, New Brunswick, also owns Bonte Foods Limited, Frank and Gino's Restaurants, and Chris Brothers food products. Established in Moncton, New Brunswick in 1977, Greco Pizza is one of Atlantic Canada's largest pizza chains. Menu items include pizza, donair, salads, garlic fingers, and the restaurant's proprietary dipping sauces. Many of the over 170 locations in Quebec, Ontario, New Brunswick, Nova Scotia, and Newfoundland operate co-branded with Captain Submarine. Both are quick-service restaurants. Captain Submarine was acquired by Grinner's in 2002, when it only had nine locations (21 fewer than it had in the 1980s). Many of the stores franchised since then also sell Greco Pizza items. The purchase brought the number of Grinners franchised restaurants from 111 to 120.

=== Acid coagulants === Glucono delta-lactone (GDL) is a naturally occurring organic acid also used in cheesemaking, this coagulant produces a very fine textured tofu that is almost jelly-like. It is used especially for "silken" and softer tofus and confers a faint sour taste to the finished product. GDL is derived from glucose and takes the form of a white powder at room temperature. Its molecular structure contains a six-membered heterocyclic ring that is hydrolyzed upon contact with water, slowly converting GDL to gluconic acid. When added to soy milk, it gradually lowers the pH and causes proteins to coagulate evenly throughout the mixture, forming a single, smooth gel that is free of air gaps and that resists breaking during transportation. Using GDL as a coagulant, silken tofu can be formed directly in its container, as it does not require pressing. This acid coagulant is also commonly used together with calcium sulfate to give soft tofu a smooth, tender texture. Other edible acids can be used. Though they can affect the taste of the tofu more, and vary in density and texture, acids such as acetic acid (vinegar) and citric acid (such as lemon juice), can also be used to coagulate soy milk and produce tofu.

=== Fermentation === The company Evolva has developed a genetically modified yeast which can produce vanillin. Because the microbe is a processing aid, the resulting vanillin would not fall under U.S. GMO labeling requirements, and because the production is nonpetrochemical, food using the ingredient can be said to contain no artificial ingredients. The biosynthetic process starts with glucose, or any sugar that can be converted into erythrose 4-phosphate (which leads to 3-dehydroshikimic acid). The end product is 98% pure and is also considered natural in the EU. Using ferulic acid (a chemical found in rice) as an input and a specific non GMO species of Amycolatopsis bacteria, vanillin can be produced. Many other bacteria, either GMO or non-GMO, can be used for the same purpose. However, because vanillin inhibits the growth of free-floating bacteria, yields have been low. This can be overcome through the formation of biofilms, which has been done with the non-GMO B. subtilis strain CCTCC M2011162. However, using ferulic acid as the starting material does not qualify for "natural ingredient" in the EU. Biotransformation of eugenol (from cloves) into vanillin by non-GMO microorganisms has also been reported. The same has been reported for guaiacol and guaicyl lignin (from conifers). These starting materials do not qualify for "natural ingredient" in the EU.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.

Is SR9009 approved for human use?

No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.

Why is SR9009 banned in sport?

The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.

How is SR9009 detected in samples?

Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.

Network